

Lonza Expands its Capsugel® Capsule Offering to Include Titanium Dioxide-Free White Hard Gelatin Capsules

- New hard gelatin capsule provides a bright white color, while meeting titanium dioxide-free requirements for foods in the European Union
- The new capsule features an alternative opacifying technology, offering an excellent masking solution, and has a superior protection of the fill formulation from light.

Basel, Switzerland, 09 May 2022 – Lonza has expanded its Capsugel® offering with a titanium dioxide-free (TiO₂-free) white hard gelatin capsule, fulfilling the evolving demand of its customers to meet new titanium dioxide-free requirements for foods in the European Union.

This novel opacifying technology leverages the functionality of crystalized salts to provide the same whiteness and masking as capsules containing TiO₂. In an internal head-to-head comparison study, Lonza’s TiO₂ alternative solution provided excellent light protection and opacity compared to other TiO₂ alternatives as well as capsules produced with TiO₂.

Stef Vanquickenborne, Vice President, Head of Capsules & Health Ingredients Research and Development, Lonza commented: “As a leader in capsule design and manufacturing, we have leveraged our experience and expertise to develop a opacifying formulation to meet the evolving requirements of our customers. This new capsule joins an already existing offering of titanium dioxide-free capsules including Capsugel® White Opal® HPMC capsule.”

Chart 1




Table 1

Capsule samples	Opacity (contrast ratio*)
Reference	68
Lonza's solution	71
Common TiO ₂ alternative	26

*Contrast Ratio = apparent reflectance of the material backed by a perfectly absorbing surface (black) divided by its apparent reflectance when backed by highly reflecting material (white).

About Lonza

Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 employees (full-time-equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. Find out more at www.lonza.com

Follow @Lonza on [LinkedIn](#)

Follow @LonzaGroup on [Twitter](#)

Lonza Contact Details

Victoria Morgan

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 2283

victoria.morgan@lonza.com

Dirk Oehlers

Investor Relations

Lonza Group Ltd

Tel +41 61 316 8540

dirk.oehlers@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.